雖然這篇Finerenone ppt鄉民發文沒有被收入到精華區:在Finerenone ppt這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Finerenone ppt是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1腎臟內科實證醫學實作報告
Finerenone. ○. More selective. ○. Less side effects. ○. In a phase IIa clinical trials in patients with heart failure and mild renal dysfunction, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Finerenone in Predominantly Advanced CKD and Type 2 ...
CV, cardiovascular; SGLT-2i, sodium-glucose cotransporter-2 inhibitor. View Large Image; Figure Viewer; Download Hi-res image · Download (PPT).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Presentation title goes here - Clinical Trial Results
Effect of finerenone on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes: results of the
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4New analyses of the comprehensive finerenone clinical trial ...
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Cardiovascular Events with Finerenone in Kidney Disease ...
Abstract Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Finerenone in Reducing Kidney Failure and Disease ...
The FIDELIO-DKD trial showed that finerenone has salutary effects on CV and renal outcomes among patients with T2DM and CKD, who were on a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Finerenone and Cardiovascular Outcomes in Patients With ...
Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Finerenone: Fiddling With Hyperkalemia? - American Journal ...
Finerenone was recently approved by the US Food and Drug Administration for treatment of diabetic kidney disease (DKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9糖尿病腎病變的診斷與治療 - 內科醫學會
Effect of finerenone on albuminuria in patients with diabetic nephropathy: a rand- omized clinical trial. JAMA 2015; 314: 884-94.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Finerenone Reduces New-Onset Atrial Fibrillation in Patients ...
Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Efficacy and Safety of Finerenone in Subjects With Type 2 ...
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD). The safety and scientific validity of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Design and Baseline Characteristics of ... - Karger Publishers
由 GL Bakris 著作 · 2019 · 被引用 85 次 — Methods: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial aims to assess the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13finerenone (Kerendia™) - EOCCO.com
finerenone (Kerendia). 10 mg tablets. Adjunct therapy for chronic kidney disease in type 2 diabetes. 30 tablets/30 days. 20 mg tablets. Initial Evaluation.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Nuclear receptors in renal health and disease - The Lancet
Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA); possesses anti-inflammatory and anti-fibrotic properties ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Diabetic kidney disease 2021 - SlideShare
Selective non-steroidal mineralocorticoid antagonists (finerenone) improve outcomes in diabetic kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16finerenone | Ligand page - IUPHAR/BPS Guide to ...
Comment: Finerenone (BAY 94-8862) is a next generation (first-in-class) oral, non-steroidal mineralocorticoid receptor antagonist which blocks the deleterious ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Patient Benefits And Cost Savings Predicted For ...
Finerenone (BAY 94-8862) is a selective, potent and non-steroidal MRA for the treatment of patients with DKD, currently studied in two clinical phase III ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Effects of SGLT2 inhibitors on cardiovascular outcomes in ...
Download: PPT. PowerPoint slide ... Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Kidney disease & CVD - PACE-CME
The findings from the FIGARO-DKD trial and the FIDELITY analysis with finerenone in T2DM patients across a broad spectrum of kidney disease were presented ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Finerenone: Uses, Interactions, Mechanism of Action - DrugBank
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist indicated to lower the risk of eGFR decline, end stage kidney disease, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Kidney Outcomes With Glucagon-Like Peptide-1 Receptor ...
In the FIDELIO-DKD trial, patients were treated with finerenone on top of treatment with ACEi/ARB, and the primary outcome event rate was 75.9 per 1000 patient- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Prevalence of Chronic Kidney Disease in Type 2 Diabetes
The recently completed Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial provides ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Finerenone Impedes Aldosterone-dependent Nuclear Import ...
This figure was produced using DINO. View Large Image; Figure Viewer; Download Hi-res image · Download (PPT). To validate such ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Diabetic nephropathy (kidney disease) - Diagnosis and ...
Kidney scarring. Finerenone (Kerendia) disrupts molecular activity believed to cause inflammation and tissue scarring in diabetic nephropathy.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Diabetic Nephropathy: Practice Essentials, Pathophysiology ...
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3. 383 (23):2219-29. [QxMD MEDLINE Link].
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Cardiovascular Events with Finerenone in Kidney ... - PubMed
Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Clinical Trials - Hot Lines at ESC Congress - European ...
FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes · FIDELITY Analysis: finerenone in mild-to-severe chronic kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Amplification of the presentation of the main results of the ...
FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven Phase III study that investigated finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Novel therapies for diabetic kidney disease
In contrast, finerenone is a nonsteroidal MRA with greater receptor ... of finerenone on diabetic nephropathy and cardiovascular outcomes,.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Finerenone Cuts CV Events in CKD Patients With Diabetes
The addition of finerenone to standard medical therapy significantly reduces the risk of cardiovascular mortality and other cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31CPG Management of Chronic Kidney Disease (Second ...
which occur less in selective AA e.g. eplerenone and finerenone.9; 36, level I In. DKD patients on RAS blockade, additional finerenone reduces urine.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32FIDELIO-DKD: Finerenone offers new treatment option for ...
FIDELIO-DKD: The mineralocorticoid receptor antagonist finerenone reduces the risk for progression of chronic kidney disease in people with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Finerenone - Wikipedia
Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34ADA Diabetes Standards of Care 2022 Guideline Summary
... receptor antagonist (finerenone) is recommended to reduce chronic kidney disease progression and cardiovascular events (Table 9.2). A
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Mineralocorticoid receptor antagonism improves diastolic ...
Finerenone is a new non-steroidal MRA that shows fewer hyperkaliaemic ... CKD was induced by subtotal nephrectomy (Nx), and finerenone was ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Pharmacy Practice Faculty Publications
CONCLUSIONS: Finerenone offers a unique approach to further delay the ... Future research should assess the individual role of CBT and PPT in CAD ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37The myeloid mineralocorticoid receptor controls inflammatory ...
Figure 1Finerenone protects against the transition from acute kidney injury to chronic kidney disease. Renal function was determined by ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Finerenone in Diabetic Nephropathy - NephJC
finerenone ; fidelio; randomized controlled trial; RCT; NEJM; diabetes; diabetic nephropathy; diabetic CKD; kidney failure; hyperkalemia.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Bayer's FIDELIO-DKD Phase III Study Demonstrated ...
Bayer's FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40ACC 2021 Late Breaking Cardiology Study Results | DAIC
Finerenone May Delay New Onset Of Atrial Fibrillation Or Flutter In Patients With Chronic Kidney Disease And Type 2 Diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41PPT (Water-Heme Modulator) - Glixx Laboratories
PPT (Water-Heme Modulator) ... BMS-654457 [1004551-41-0] · 5-HT7R Antagonist 2c · Finerenone [1050477-31-0] · EL-0052 · DX2-HSP70 inhibitor-1 [125105-17-1] ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42finerenone | Ligand page - IUPHAR/MMV Guide to MALARIA ...
Comment: Finerenone (BAY 94-8862) is a next generation (first-in-class) oral, non-steroidal mineralocorticoid receptor antagonist which blocks the deleterious ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#432021 J.P. MORGAN HEALTHCARE CONFERENCE: REVIEW
to support the life cycle management of Eylea, Stivarga, and Finerenone and announcing positive Phase III trial results for multiple ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Nierbeschermende behandeling bij chronische nierschade
Finerenone en “the potassium issue”. • Klinische trial in DKD met de ERA atrasentan: SONAR. • Atrasentan en “the sodium issue”.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Results of ARTS-HF: finerenone versus eplerenone in patients ...
Download ppt "Results of ARTS-HF: finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and/or chronic kidney disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46FIGARO-DKD研究重磅发布!Finerenone显著改善2型糖尿病合并 ...
本届ESC年会公布的FIGARO-DKD研究结果显示,Finerenone显著降低了T2D合并轻中度CKD患者首次发生心血管死亡或非致死性事件(心血管死亡、心肌梗死、卒中或因心力衰竭住院) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47esc慢性心衰的药物治疗ppt课件- 豆丁网
Finerenone 是一种新型非甾体盐皮质激素受体拮抗剂,体外实验发现其受体选择性大于安体舒通,丐受体亲和力优于依普利酮ESC 2015:第3代MRA研究进展MRA分代丼例/归类选择 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Edgar V. Lerma 在Twitter 上:"FIDELIO-DKD and FIGARO ...
FIDELIO-DKD: Effect of Finerenone on CKD Outcomes in Type 2 Diabetes ca. 2020 from @NEJM @BakrisGeorge @AgarwalRajivMD #KidneyWk ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49soi cầu 3 số miền nam - Tạp chí Tia Sáng
... finerenone có lợi ích rõ ràng cho thận và tim mạch. ... Theo PPT, việc hợp tác với Amgen đã xác minh khả năng phát triển và thương mại ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50最新全民健保法規公告 - 衛生福利部中央健康保險署
刊登日期 發文日期 發文字號 登載期限 111. 02. 07 111. 02. 07 健保審字第1110772782號 114. 02. 07 111. 01. 28 111. 01. 28 健保審字第1110772891號 114. 01. 28 111. 01. 28 111. 01. 26 健保審字第1100036483號 114. 01. 28
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51wang leehom wife background ppt simple kerendia
wang leehom wife background ppt simple kerendia-related searches include not only ... ppt simple kerendia (finerenone, and wang leehom wife background ppt ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Efficacy and safety of finerenone in patients with chronic ...
Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53KERENDIA (finerenone) to Treat CKD Associated with Type 2 ...
KERENDIA (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist indicated for chronic kidney disease associated with type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54A randomized controlled study of finerenone vs. eplerenone in ...
To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Mineralocorticoid Receptor Antagonists in Diabetic Kidney ...
spironolactone; eplerenone; apararenone; esaxerenone; finerenone. 1. Introduction. Diabetes mellitus (DM) is a worldwide health issue and it ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56215341s000lbl.pdf - Accessdata.fda.gov
Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure [see. Clinical Pharmacology (12.3)], which may increase the risk of Kerendia ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
finerenone 在 コバにゃんチャンネル Youtube 的最佳解答
finerenone 在 大象中醫 Youtube 的最佳貼文
finerenone 在 大象中醫 Youtube 的精選貼文